DISCOVER WHAT REAL RELIEF LOOKS LIKE
Imagine fewer accidents and getting back to the relationships and activities one loves.
Find a Specialist
Refer to technical manual and Instruction for Use (IFU) for complete list of indications, contraindications, warnings and precautions.
BLADDER CONTROL THERAPY DELIVERED BY NEUROMODULATION
COMMUNICATION IS CRITICAL
Evidence suggests that breakdowns in the bladder-brain communication pathway are the root cause of OAB and non-obstructive urinary retention.1-3 While other therapies focus on the bladder muscles, Medtronic therapies target the nerves, which is thought to help restore normal bladder function.*
MEDTRONIC BLADDER CONTROL THERAPY DELIVERED BY THE INTERSTIM SYSTEM
When more conservative treatments fail, Medtronic Bladder Control Therapy delivered by the InterStimTM system can help. This therapy is so simple and discreet patients might forget they have it. And it delivers the kind of relief that allows enjoyment of favourite activities without a second thought.
- Targets the nerves that control your bladder to help it function normally again
- 85 percent of people using it achieved success in the first year4†
- 3X greater improvements in quality of life compared to medications5
- Only therapy that lets you see if it works before you and your doctor decide
Implanting an InterStim™ system has risks similar to any surgical procedure, including swelling, bruising, bleeding, and infection. Talk with your doctor about ways to minimize these risks.
DISCUSS BLADDER CONTROL TREATMENT OPTIONS WITH A DOCTOR
Medtronic bladder control therapy delivered by the InterStim system provides life-changing relief.
- 84% satisfaction among those who use it6
- 76% of people achieved success at 6 months compared to 49% who used
- medications5,‡
- The only OAB therapy that provides better relief than medications5,7,8
The most common adverse events experienced during clinical studies included pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.
THE PATIENT JOURNEY WITH SACRAL NEUROMODULATION THERAPY
TALK TO A SPECIALIST
Speak with a doctor in your community who can help you find the right treatment.
FIND A SPECIALIST
Bladder control problems affect millions of people. But relief is closer than you think.
SEE THE STEPSSTART THE CONVERSATION
Talking about bladder control problems can be difficult. But this doctor discussion guide can help you get through it more easily.
GET THE GUIDEWHAT IS BLADDER CONTROL THERAPY?
Read a quick overview to understand your options and see if Medtronic bladder control therapy might be right for you.
READ THE BROCHURE
VISUALISE YOUR JOURNEY
The care pathway helps you understand all of the treatment options available for bladder control problems.
DOWNLOAD THE PATHWAY
*
Restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.
†
Numbers reflect completers analysis defined as patients with diary data at baseline and 12 months (n=220). Clinical success was 82% at 12 months using the modified completers analysis (subjects who either had a baseline and 12 month evaluation or withdrew early due to device-related reasons and are considered failures).
‡
These patient groups were analyzed based on the treatment they were assigned: incomplete data was counted as ”failures.” Another analysis reported 61% of people achieved success with InterStim, compared to 42% who used medications.
1
Dasgupta R. Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral Neuromodulation for urinary retention. J Urol. 2005;174:2268–2272
2
Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005;174:1862–1867.
3
Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27(6):466–474.
4
Noblett K, Siegel S, Mangel J, et al. Results of a Prospective, Multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn. 2016 Feb;35(2):246-51.
5
Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim® Therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34:224–230. DOI: 10.1002/nau.22544.
6
Foster RT Sr, Anoia EJ, Webster GD, Amundsen CL. In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction. Neurourol Urodyn. 2007;26:213–217.
7
Visco A, Brubaker L, Richter HE et al. Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence. New Engl J Med. 2012;367(19):1803–1813.
8
Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–1061.